Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

XORTX Announces Filing of FDA pre-IND Meeting Request Letter
XORTX Announces Filing of FDA pre-IND Meeting Request Letter

Press Releases

  • XORTX Announces Notice to Grant European Patent April 6, 2021
  • XORTX to Present at “Zoom With LD MICRO” March 16, 2021
  • XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021 March 9, 2021
  • XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection March 8, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress